Stock Mover of The Day: Foundation Medicine Inc on Focus After Crashing In Today’s Session

Stock Mover of The Day: Foundation Medicine Inc on Focus After Crashing In Today's Session

The stock of Foundation Medicine Inc (NASDAQ:FMI) is a huge mover today! About 210,275 shares traded hands or 32.46% up from the average. Foundation Medicine Inc (NASDAQ:FMI) has risen 31.25% since March 8, 2016 and is uptrending. It has outperformed by 21.93% the S&P500.
The move comes after 8 months negative chart setup for the $829.08M company. It was reported on Oct, 11 by Barchart.com. We have $21.96 PT which if reached, will make NASDAQ:FMI worth $49.74 million less.

Analysts await Foundation Medicine Inc (NASDAQ:FMI) to report earnings on November, 1. They expect $-0.87 earnings per share, down 45.00% or $0.27 from last year’s $-0.6 per share. After $-0.84 actual earnings per share reported by Foundation Medicine Inc for the previous quarter, Wall Street now forecasts 3.57% negative EPS growth.

Foundation Medicine Inc (NASDAQ:FMI) Ratings Coverage

Out of 7 analysts covering Foundation Medicine (NASDAQ:FMI), 0 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 0 are positive. Foundation Medicine has been the topic of 9 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by JMP Securities given on Thursday, July 30. BTIG Research downgraded the shares of FMI in a report on Wednesday, November 4 to “Neutral” rating. The stock of Foundation Medicine Inc (NASDAQ:FMI) earned “Neutral” rating by UBS on Wednesday, September 21. Wells Fargo downgraded the shares of FMI in a report on Wednesday, September 16 to “Market Perform” rating. The firm has “Buy” rating by BTIG Research given on Monday, September 14.

According to Zacks Investment Research, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.77 in Q2 2016. Its up 0.34, from 1.43 in 2016Q1. The ratio improved, as 10 funds sold all Foundation Medicine Inc shares owned while 16 reduced positions. 4 funds bought stakes while 42 increased positions. They now own 10.32 million shares or 3.75% less from 10.73 million shares in 2016Q1.
Rhumbline Advisers accumulated 12,827 shares or 0% of the stock. Hanson And Doremus Mngmt has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Whittier Trust has 0.03% invested in the company for 39,835 shares. Spot Trading Lc owns 59,593 shares or 0.02% of their US portfolio. Metropolitan Life Insur Com Ny last reported 10,315 shares in the company. Amer reported 7,747 shares or 0% of all its holdings. Jackson Park Cap Ltd Liability Com has 12,500 shares for 0.32% of their US portfolio. Baker Bros Advsrs Lp owns 20,892 shares or 0% of their US portfolio. Moreover, Susquehanna Int Grp Inc Ltd Liability Partnership has 0% invested in Foundation Medicine Inc (NASDAQ:FMI) for 41,583 shares. Goldman Sachs Grp Inc has 21,385 shares for 0% of their US portfolio. Bank Of America Corp De has 3,032 shares for 0% of their US portfolio. Gilder Gagnon Howe & Ltd Liability has invested 0.75% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Zurcher Kantonalbank (Zurich Cantonalbank) has 122,264 shares for 0.03% of their US portfolio. State Street Corporation has 0% invested in the company for 201,473 shares. Tiaa Cref Inv Mngmt Ltd Liability Corporation has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI).

More important recent Foundation Medicine Inc (NASDAQ:FMI) news were published by: Seekingalpha.com which released: “Foundation Medicine: Excellent Risk/Reward Ratios” on October 04, 2016, also Businesswire.com published article titled: “Foundation Medicine Reports Preliminary 2015 Results and Provides 2016 …”, Reuters.com published: “BRIEF-Foundation Medicine Inc – FoundationOne accepted by FDA and CMS for …” on August 02, 2016. More interesting news about Foundation Medicine Inc (NASDAQ:FMI) was released by: Businesswire.com and their article: “Foundation Medicine Announces National Agreement with UnitedHealthcare for …” with publication date: December 21, 2015.

FMI Company Profile

Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. The Company’s products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The Company’s flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment